Hypolipidemic drug clofibrate promotes hepatic tumor.
In diethylnitrosamine-initiated rats, administration of clofibrate for 32 weeks induced neoplastic lesions and hepatocellular carcinoma. In contrast to conventional carcinogens, clofibrate effected a marked decrease in the activity of gamma-glutamyltranspeptidase. Ornithine was selectively channeled into polyamine synthesis with concomitant repression of the urea cycle and the transamination pathway. These histological and biochemical studies suggest that clofibrate acts as a promoting agent in hepatocarcinogenesis.